Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

391 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Multicenter prospective risk-adapted study on the therapy of non-Hodgkin's lymphomas of high malignancy. Use of COP-BLAM/IMVP-16 and randomized adjuvant radiotherapy--study concept and preliminary results].
Siegert W, Huhn D, Neubauer A, Brittinger G, Engelhard M, Gerhartz H, Heinz R, Meusers P, Stacher A, Thiel E, et al. Siegert W, et al. Among authors: huhn d. Onkologie. 1988 Feb;11(1):30-4. doi: 10.1159/000216476. Onkologie. 1988. PMID: 2452392 Clinical Trial. German.
Cytokine efficiency in the treatment of high-grade malignant non-Hodgkin's lymphomas: results of a randomized double-blind placebo-controlled study with intensified COP-BLAM +/- rhGM-CSF.
Engelhard M, Gerhartz H, Brittinger G, Engert A, Fuchs R, Geiseler B, Gerhartz D, Haunauske AR, Hartlapp HJ, Huhn D, et al. Engelhard M, et al. Among authors: huhn d. Ann Oncol. 1994;5 Suppl 2:123-5. doi: 10.1093/annonc/5.suppl_2.s123. Ann Oncol. 1994. PMID: 7515644 Clinical Trial.
Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non-Hodgkin's lymphomas.
Gerhartz HH, Engelhard M, Meusers P, Brittinger G, Wilmanns W, Schlimok G, Mueller P, Huhn D, Musch R, Siegert W, et al. Gerhartz HH, et al. Among authors: huhn d. Blood. 1993 Oct 15;82(8):2329-39. Blood. 1993. PMID: 7691256 Free article. Clinical Trial.
Subclassification of diffuse large B-cell lymphomas according to the Kiel classification: distinction of centroblastic and immunoblastic lymphomas is a significant prognostic risk factor.
Engelhard M, Brittinger G, Huhn D, Gerhartz HH, Meusers P, Siegert W, Thiel E, Wilmanns W, Aydemir U, Bierwolf S, Griesser H, Tiemann M, Lennert K. Engelhard M, et al. Among authors: huhn d. Blood. 1997 Apr 1;89(7):2291-7. Blood. 1997. PMID: 9116271 Free article. Clinical Trial.
Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM/IMVP-16 regimen. A multicenter study. Kiel Lymphoma Study Group.
Siegert W, Agthe A, Griesser H, Schwerdtfeger R, Brittinger G, Engelhard M, Kuse R, Tiemann M, Lennert K, Huhn D. Siegert W, et al. Among authors: huhn d. Ann Intern Med. 1992 Sep 1;117(5):364-70. doi: 10.7326/0003-4819-117-5-364. Ann Intern Med. 1992. PMID: 1380221 Clinical Trial.
Peripheral T-cell non-Hodgkin's lymphomas of low malignancy: prospective study of 25 patients with pleomorphic small cell lymphoma, lymphoepitheloid cell (Lennert's) lymphoma and T-zone lymphoma. The Kiel Lymphoma Study Group.
Siegert W, Nerl C, Engelhard M, Brittinger G, Tiemann M, Parwaresch R, Heinz R, Huhn D. Siegert W, et al. Among authors: huhn d. Br J Haematol. 1994 Jul;87(3):529-34. doi: 10.1111/j.1365-2141.1994.tb08308.x. Br J Haematol. 1994. PMID: 7527646 Clinical Trial.
391 results